PDE5A and cirrhosis of liver: Preclinical and clinical data provide evidence that targeting sCG (stimulators or activators) or PDE-5 inhibitors in liver cirrhosis lowers portal pressure and intrahepatic resistance, thereby increasing sinusoidal blood flow.